Trasplante de Progenitores Hematopoyéticos y Clínica de Hemopatías Malignas.

Publicaciones en 2017 / Publicaciones en 2016 / Publicaciones en 2015

Publicaciones en 2017

Español I, Romera M, Gutiérrez-Meca MD, García MDC, Tejedor A, Martínez A, Ibáñez J, De Arriba F, Minguela A, Iturbe T, López MD. Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement. Clin Case Rep. 2017 Jun 22;5(8):1258-1260. doi: 10.1002/ccr3.1015. eCollection 2017 Aug. PMID: 28781837

Ribera JM, Morgades M, Montesinos P, Martino R, Barba P, Soria B, Bermúdez A, Moreno MJ, González-Campos J, Vives S, Gil C, Abella E, Guàrdia R, Martínez-Carballeira D, Martínez-Sánchez P, Amigo ML, Mercadal S, Serrano A, López-Martínez A, Vall-Llovera F, Sánchez-Sánchez MJ, Peñarrubia MJ, Calbacho M, Méndez JA, Bergua J, Cladera A, Tormo M, García-Belmonte D, Feliu E, Ciudad J, Orfao A; PETHEMA Group, Spanish Society of Hematology. Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia. Leuk Lymphoma. 2017 Nov 22:1-10. doi: 10.1080/10428194.2017.1397661. [Epub ahead of print] PMID: 29165013

Gallardo D, Bosch-Vizcaya A, Rodríguez-Romanos R, Santos N, Buño I, de la Cámara R, Brunet S, Jiménez-Velasco A, González M, Nieto JB, Martínez-Laperche C, Vallejo C, Ferrá C, Sampol A, López-Jiménez J, Pérez-Simón JA, Martínez C, Díez JL. Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. Biol Blood Marrow Transplant. 2017 Dec;23(12):2042-2047. doi: 10.1016/j.bbmt.2017.08.003. Epub 2017 Aug 4. PMID: 28827064

Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. PMID: 28801448

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E; PETHEMA Group, Spanish Society of Hematology. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2018 Jan;59(1):146-154. doi: 10.1080/10428194.2017.1326596. PMID: 2855425

Sanikommu SR, Clemente MJ, Chomczynski P, Afable MG 2nd, Jerez A, Thota S, Patel B, Hirsch C, Nazha A, Desamito J, Lichtin A, Pohlman B, Sekeres MA, Radivoyevitch T, Maciejewski JP. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk Lymphoma. 2018 Feb;59(2):416-422. doi: 10.1080/10428194.2017.1339880. PMID: 28633612

Osorio S, Escudero-Vilaplana V, Reguilón-Gallego L, Gómez-Centurión I, Díez JL, Ferrer-Marín F. Severe liver toxicity in a chronic myeloid leukemia patient probably induced by a drug interaction between imatinib and sertraline. J Oncol Pharm Pract. 2017 Jan 1:1078155217735689. doi: 10.1177/1078155217735689. PMID: 29065786

Hernández-Boluda JC, Pereira A, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Pérez-Encinas M, Estrada N, Velez P, Fox ML, García-Gutiérrez V, Payer A, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares MT, Mata-Vázquez MI, Mora E, Martínez-Valverde C, Gómez M, Cervantes F. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia. 2017 Sep 22. doi: 10.1038/leu.2017.297. PMID: 28935991

Alonso-Dominguez JM, Casado LF, Anguita E, Gomez-Casares MT, Buño I, Ferrer-Marín F, Arenas A, Del Orbe R, Ayala R, Llamas P, Salgado RN, Osorio S, Sanchez-Godoy P, Burgaleta C, Mahíllo-Fernández I, Garcia-Gutierrez V, Steegmann JL, Martinez-Lopez J. PTCH1 is a reliable marker for predicting imatinib response in chronic myeloid leukemia patients in chronic phase. PLoS One. 2017 Jul 13;12(7):e0181366. doi: 10.1371/journal.pone.0181366. PMID: 28704552

Alvarez-Larrán A, Senín A, Fernández-Rodríguez C, Pereira A, Arellano-Rodrigo E, Gómez M, Ferrer-Marin F, Martínez-López J, Camacho L, Colomer D, Angona A, Navarro B, Cervantes F, Besses C, Bellosillo B, Hernández-Boluda JC. Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2017 Sep;178(5):764-771. doi: 10.1111/bjh.14762. PMID: 28542718

Hernández-Boluda JC, Correa JG, Alvarez-Larrán A, Ferrer-Marín F, Raya JM, Martínez-López J, Velez P, Pérez-Encinas M, Estrada N, García-Gutiérrez V, Fox ML, Luño E, Kerguelen A, Cuevas B, Durán MA, Ramírez MJ, Gómez-Casares M, Mata-Vázquez MI, Regadera A, Pereira A, Cervantes F; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN). Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14601. PMID: 28419426

Hernández-Boluda JC, Correa JG, García-Delgado R, Martínez-López J, Alvarez-Larrán A, Fox ML, García-Gutiérrez V, Pérez-Encinas M, Ferrer-Marín F, Mata-Vázquez MI, Raya JM, Estrada N, García S, Kerguelen A, Durán MA, Albors M, Cervantes F.Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. Eur J Haematol. 2017 Apr;98(4):407-414. doi: 10.1111/ejh.12846. PMID: 28009442

Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marín F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-Gutiérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martínez C, Albors M, García F, Burgaleta C, Besses C; Grupo Español de Neoplasias Mieloproliferativas Filadelfia Negativas. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. Haematologica. 2017 Jan;102(1):103-109. doi: 10.3324/haematol.2016.152769. PMID: 27686377

Español I, Romera M, Gutiérrez-Meca MD, García MDC, Tejedor A, Martínez A, Ibáñez J, De Arriba F, Minguela A, Iturbe T, López MD. Carfilzomib and dexamethasone for extramedullary myeloma with pleuropericardial involvement. Clin Case Rep. 2017 Jun 22;5(8):1258-1260. doi: 10.1002/ccr3.1015. PMID: 28781837

Chen-Liang TH, Martín-Santos T, Jerez A, Rodríguez-García G, Senent L, Martínez-Millán C, Muiña B, Orero M, Teruel A, Martín A, Gómez-Espuch J, Kennedy K, Benet C, Raya JM, Fernández-González M, de la Cruz F, Guinot M, Villegas C, Ballester I, Baile M, Moya M, López-Jiménez J, Frutos L, Navarro JL, Uña J, Fernández-López R, Igua C, Contreras J, Sánchez-Vañó R, Cozar MDP, Tamayo P, Mucientes J, Sánchez-Blanco JJ, Pérez-Ceballos E, Ortuño FJ. Bone marrow biopsy superiority over PET/CT in predicting progression-free survival in a homogeneously-treated cohort of diffuse large B-cell lymphoma. Cancer Med. 2017 Sep 27. doi: 10.1002/cam4.1205. PMID: 28960797

Gutiérrez-Cívicos R, Hurtado AM, Torres-Moreno D, Sanchez-Blanco JJ, Español I, Consuegra-Sánchez L, Perez-Ceballos E, Gutiérrez-Meca MD, Jerez A, Conesa-Zamora P. Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. Pharmacogenet Genomics. 2017 Feb;27(2):70-77. doi: 10.1097/FPC.0000000000000262. PMID: 27977511

Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA. Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant. 2017 Mar;52(3):438-444. doi: 10.1038/bmt.2016.269. PMID: 27819684

Gallardo D, Bosch-Vizcaya A, Rodríguez-Romanos R, Santos N, Buño I, de la Cámara R, Brunet S, Jiménez-Velasco A, González M, Nieto JB, Martínez-Laperche C, Vallejo C, Ferrá C, Sampol A, López-Jiménez J, Pérez-Simón JA, Martínez C, Díez JL; GvHD/Immunotherapy Committee of the Spanish Hematopoietic Transplant Group. Donor CTLA-4 Genotype Modulates the Immune Response to Minor Histocompatibility Antigen Mismatches. Biol Blood Marrow Transplant. 2017 Aug 4. pii: S1083-8791(17)30618-3. doi: 10.1016/j.bbmt.2017.08.003. PMID: 28827064

Kwon M, Bautista G, Balsalobre P, Sánchez-Ortega I, Montesinos P, Bermúdez A, de Laiglesia A, Herrera P, Martin C, Humala K, Zabalza A, Torres M, Bento L, Corral LL, Heras I, Serrano D, Buño I, Anguita J, Regidor C, Duarte R, Cabrera R, Gayoso J, Diez-Martin JL. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. Bone Marrow Transplant. 2017 Mar 27. doi: 10.1038/bmt.2017.36. PMID: 28346415

Cabrero M, Martin A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial. Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. PMID: 27771496

Lahuerta JJ, Paiva B, Vidriales MB, Cordón L, Cedena MT, Puig N, Martinez-Lopez J, Rosiñol L, Gutierrez NC, Martín-Ramos ML, Oriol A, Teruel AI, Echeveste MA, de Paz R, de Arriba F, Hernandez MT, Palomera L, Martinez R, Martin A, Alegre A, De la Rubia J, Orfao A, Mateos MV, Blade J, San-Miguel JF. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol. 2017 May 12:JCO2016692517. doi: 10.1200/JCO.2016.69.2517. PMID: 28498784

Rosiñol L, Oriol A, Teruel AI, de la Guía AL, Blanchard M, de la Rubia J, Granell M, Sampol M, Palomera L, González Y, Etxebeste M, Martínez-Martínez R, Hernández MT, de Arriba F, Alegre A, Cibeira M, Mateos M, Martínez-López J, Lahuerta JJ, San Miguel J, Bladé J. Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial. Leukemia. 2017 Feb 14. doi: 10.1038/leu.2017.35. PMID: 28111466.

Mateos MV, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Ann Hematol. 2016 Dec;95(12):2033-2041. PMID: 27738789.

González-Gascón Y Marín I, Martín AÁ, Hernández-Sanchez M, Robledo C, Hermosín ML, de Las Heras N, Lacalle L, Galende J, de Arriba F, Rodríguez-Vicente AE, Hernández JÁ, Hernández-Rivas JM. Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL. Eur J Haematol. 2017 Feb;98(2):142-148. doi: 10.1111/ejh.12812.

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Blanco ML, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu M, Ferrer A, Sanz GF, Florensa L. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R). Am J Hematol. 2017 Jul;92(7):614-621. doi: 10.1002/ajh.24732. PMID: 28370234

Hosono N, Makishima H, Mahfouz R, Przychodzen B, Yoshida K, Jerez A, LaFramboise T, Polprasert C, Clemente MJ, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Cui E, Verma AK, McDevitt MA, List AF, Saunthararajah Y, Sekeres MA, Boultwood J, Ogawa S, Maciejewski JP. Recurrent genetic defects on chromosome 5q in myeloid neoplasms. Oncotarget. 2017 Jan 24;8(4):6483-6495. doi: 10.18632/oncotarget.14130. PMID: 28031539

Gutiérrez-Cívicos R, Hurtado AM, Torres-Moreno D, Sanchez-Blanco JJ, Español I, Consuegra-Sánchez L, Perez-Ceballos E, Gutiérrez-Meca MD, Jerez A, Conesa-Zamora P.Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger. Pharmacogenet Genomics. 2017 Feb;27(2):70-77. doi: 10.1097/FPC.0000000000000262. PMID: 27977511

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Mercadal S, González-Campos J, Moreno MJ, Barba P, Cervera M, Barrios M, Novo A, Bernal T, Hernández-Rivas JM, Abella E, Amigo ML, Tormo M, Martino R, Lavilla E, Bergua J, Serrano A, García-Belmonte D, Guàrdia R, Grau J, Feliu E; PETHEMA Group, Spanish Society of Hematology. Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326596. PMID: 28554259

Sanchez R, Ayala R, Alonso RA, Martínez MP, Ribera J, García O, Sanchez-Pina J, Mercadal S, Montesinos P, Martino R, Barba P, González-Campos J, Barrios M, Lavilla E, Gil C, Bernal T, Escoda L, Abella E, Amigo ML, Moreno MJ, Bravo P, Guàrdia R, Hernández-Rivas JM, García-Guiñón A, Piernas S, Ribera JM, Martínez-López J.Clinical characteristics of patients with central nervous system relapse in BCR-ABL1-positive acute lymphoblastic leukemia: the importance of characterizing ABL1 mutations in cerebrospinal fluid. Ann Hematol. 2017 Jul;96(7):1069-1075. doi: 10.1007/s00277-017-3002-1. PMID: 28451802

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leuk Lymphoma. 2017 Jan;58(1):145-152. PMID: 27122129

Martínez C, Jorge AS, Pereira A, Moreno M, Núñez J, Gayoso J, Gonzalez-Medina J, Revilla N, Sampol A, Domingo-Domenech E, de la Cruz F, Morales A, Rodriguez-Salazar MJ, Valiente S, Pérez-Ceballos E, de Oteyza JP, García-Sanz R. Comorbidities, not age, are predictive of survival after autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years. Ann Hematol. 2017 Jan;96(1):9-16. doi: 10.1007/s00277-016-2832-6. PMID: 27752822

Puiggros A, Collado R, Calasanz MJ, Ortega M, Ruiz-Xivillé N, Rivas-Delgado A, Luño E, González T, Navarro B, García-Malo M, Valiente A, Hernández JÁ, Ardanaz MT, Piñan MÁ, Blanco ML, Hernández-Sánchez M, Batlle-López A, Salgado R, Salido M, Ferrer A, Abrisqueta P, Gimeno E, Abella E, Ferrá C, Terol MJ, Ortuño F, Costa D, Moreno C, Carbonell F, Bosch F, Delgado J, Espinet B. Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ ATM FISH deletions. Oncotarget. 2017 Apr 21. doi: 10.18632/oncotarget.17350. PMID: 28493833

Baptista MJ, Granada I, Morgades M, Calasanz MJ, Canals J, Robles De Castro D, Luño E, Ruiz-Xivillé N, Rodríguez-Hernández I, González T, Terol MJ, Valiente A, Ortuño F, Garcia-Malo MD, Piñan MÁ, Oliveira AC, Talavera M, Buño I, Batlle-López A, Moreno C, Ferra C, Solé F. Monosomal karyotype in chronic lymphocytic leukemia: Association with clinical and biological features and potential prognostic significance. Am J Hematol. 2017 Jul;92(7):E132-E135. doi: 10.1002/ajh.24754. PMID: 28383114

Publicaciones en 2016

Caballero-Velázquez T, Montero I, Sánchez-Guijo F, Parody R, Saldaña R, Valcarcel D, López-Godino O, Ferra I Coll C, Cuesta M, Carrillo-Vico A, Sánchez-Abarca LI, López-Corral L, Márquez-Malaver FJ, Pérez-Simón JA; GETH (Grupo Español de Trasplante Hematopoyético).IMMUNOMODULATORY EFFECT OF VITAMIN D AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: RESULTS OF A PROSPECTIVEMULTICENTER CLINICAL TRIAL. Clin Cancer Res. 2016 Dec 1;22(23):5673-5681

Parody R, López-Corral L, Lopez-Godino O, Martinez C, Martino R, Solano C, Barba P, Caballero D, García-Cadenas I, Piñana JL, Marquez-Malaver FJ, Vazquez L, Esquirol A, Boluda JC, Sanchez-Guijo F, Pérez-Simon JA. GVHD PROPHYLAXIS WITH TACROLIMUS PLUS SIROLIMUS AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC TRANSPLANTATION: RESULTS OF A MULTICENTER STUDY. Bone Marrow Transplant. 2016 Nov;51(11):1524-1526

Velasco-Guardado A, Mora-Soler A, López-Corral L, López-Godino O, Vázquez-López L, Blanco-Muñez O, Pérez-López E, Rodríguez-Pérez A, Caballero-Barrigón D. POTENTIAL PROTECTIVE EFFECT OF HELICOBACTER PYLORI ON THE DEVELOPMENT OF GASTROINTESTINAL GRAFT VERSUS HOST DISEASE. Bone Marrow Transplant. 2016 Jun;51(6):819-24.

Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F,Xicoy B, Alvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F. Long-term results of prednisone treatment for the anemia of myelofibrosis. Leuk Lymphoma. 2016; 57 (1): 120-4.

M, Barba P, Mata MI, González-Porras JR, Ferrer-Marín F, García-Gutiérrez V, Magro E, Moreno M, Kerguelen A, Pérez-Encinas M, Estrada N, Ayala R, Besses C, Pereira A; Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas(GEMFIN).

Santos N, Rodríguez-Romanos R, Nieto JB, Buño I, Vallejo C, Jiménez-Velasco A, Brunet S, Buces E, López-Jiménez J, González M, Ferrá C, Sampol A, de la Cámara R, Martínez C, Gallardo D. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation. Bone Marrow Transplant. 2016; 51 (1): 79-82.

Bosch-Vizcaya A, Rodriguez-Romanos R, Nieto JB, de la Cámara R, Brunet S, Vallejo C, Osca-Gelis G, Martínez-Laperche C, Buño I, Urbano-Ispizúa Á, González M, Jiménez-Velasco A, Gallardo D. Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT.Bone Marrow Transplant. 2015; 50 (2): 298-300.

Muñoz-Ballester J, Chen-Liang TH, Hurtado AM, Heras I, de Arriba F, García-Malo MD, Iniesta P, Lozano ML, Nieto JB, Ortuño FJ, Osma MD, Padilla J, Teruel-Montoya R, Vicente V, Castilla-Llorente C, Jerez A. Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations.Br J Haematol. 2016; 172 (6): 937-946.

Torregrosa JM, Ferrer-Marín F, Lozano ML, Moreno MJ, Martinez C, Anton AI, Rivera J, Vicente V.Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation.Br J Haematol.2016;172 (5): 813-815.

Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ortín X, Pedreño M, Amigo ML, Escoda L, Feliu E; PETHEMA Group, Spanish Society of Hematology. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group.Leuk Res. 2016; 41:12-20.

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.Eur J Haematol. 2016; 97 (1): 33-38.

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV. Recommendations on the clinical use of bendamustine in lymphoproliferative syndromes and multiple myeloma. Eur J Haematol. 2016; 96 (5): 532-540.

Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT, Bargay J, de Arriba F, De La Rubia J, Teruel AI, Giraldo P, Rosiñol L, Prosper F, Oriol A, Hernández J, Esteves G, Lahuerta JJ, Blade J, Perez- Simon JA, San Miguel JF. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis.Blood 2016; 127 (9): 1151-1162.

Gómez M, Guillem V, Pereira A, Ferrer-Marín F, Álvarez-Larrán A, Kerguelen A, Estrada N, Martínez-López J, Angona A, Amat P, Navarro B, Besses C, Hernández- Boluda JC. Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2016; 96 (3): 285-290. Álvarez-Román MT, Rivas Pollmar MI, Bernardino JI, Lozano ML, Martín-Salces M, Fernández-Bello I, Jiménez-Yuste V, Butta NV. Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia.AIDS. 2016; 30 (7): 1141-1142.

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology. Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols. Leuk Lymphoma. 2016; 27:1-8.

Gutiérrez-Cívicos R, Hurtado AM, Torres-Moreno D, Sanchez-Blanco JJ, Español I, Consuegra-Sánchez L, Perez-Ceballos E, Gutiérrez-Meca MD, Jerez A, Conesa-Zamora P. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients. Am J Hematol. 2016; 91 (6):E305-7

Lozano ML, Revilla N, Gonzalez-Lopez TJ, Novelli S, González-Porras JR, Sánchez- Gonzalez B, Bermejo N, Pérez S, Lucas FJ, Álvarez MT, Arilla MJ, Perera M, do Nascimento J, Campos RM, Casado LF, Vicente V. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Ann Hematol. 2016; 95 (7): 1089-98.

Besses C, Hernández-Boluda JC, Pérez Encinas M, Raya JM, Hernández-Rivas JM, Jiménez Velasco A, Martínez Lopez J, Vicente V, Burgaleta C; Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.GEMFIN. Ann Hematol. 2016; 95 (5):719-32.

Villegas A, Arrizabalaga B, Bonanad S, Colado E, Gaya A, González A, Jarque I, Núñez R, Ojeda E, Orfao A, Ribera JM, Vicente V, Urbano-Ispizua Á; Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria Grupo de Trabajo de HPN de la Sociedad Española de Hematología y Hemoterapia. Med Clin (Barc). 2016;146(6):278.e1-7.

Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF; Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (GEM/PETHEMA) Cooperative Study Groups. Blood. 2016;127 (15):1896-906.

D.Navarro,P. Amat, R. de la Cámara, J. López, L. Vázquez, D. Serrano, J. Nieto,. Rovira, J. L Piñana, E. Giménez, and C. Solano. Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients. Open Forum Infectious Diseases 2016 May 18;3(2):ofw107.

Corrales I, Solano C, Amat P, Giménez E, de la Cámara R, Nieto J, López J, García-Noblejas A, Piñana JL, Navarro D. IL28B genetic variation and cytomegalovirus-specific T-cell immunity in allogeneic stem cell transplant recipients. J Med Virol. 2016 Sep 3. doi: 10.1002/jmv.24676.

Cabrero M, Martín A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D. Phase II Study of Yjrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity CondiMoning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic TransplantaMon in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial. Biol Blood Marrow Transplant. 2016 Oct 19. pii: S1083-8791

Gayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, Serrano D, Piñana JL, Herrera P, Ferrá C, Pascual C, Heras I, Montesinos P, Zabalza A, Bento L, Figuera A, Buño I, Díez-Martín JL. Busulfan-based reduced intensity condiMoning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant. 2016 Oct;51(10):1307-1312.

Mateos MV, Oriol A, Martínez-López J, Teruel AI, Bengoechea E, Palomera L, de Arriba F, Esseltine DL, Cakana A, Pei L, van de Velde H, Miguel JS. Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials. Ann Hematol. 2016 Dec;95(12):2033-2041.

Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, Corral LL, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Arguiñano JM, Quintana N, García JL, Bladé J, Lahuerta JJ, Miguel JF. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): longterm follow-up of a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 Aug;17(8):1127-36.

Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, Weisel KC, Oriol A, Hansson M, Vacca A, Blanchard MJ, Goldschmidt H, Doyen C, Kaiser M, Petrini M, Anyla P, Cafro AM, Raymakers R, San-Miguel J, de Arriba F, Knop S, Röllig C, Ocio EM, Morgan G, Miller N, Simcock M, Peluso T, Herring J, Sternas L, Zaki MH, Moreau P. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016 Jul 28;128(4):497-503.

Paiva B, Corchete LA, Vidriales MB, Puig N, Maiso P, Rodriguez I, Alignani D, Burgos L, Sanchez ML, Barcena P, Echeveste MA, Hernandez MT, García-Sanz R, Ocio EM, Oriol A, Gironella M, Palomera L, De Arriba F, Gonzalez Y, Johnson SK, Epstein J, Barlogie B, Lahuerta JJ, Blade J, Orfao A, Mateos MV, San Miguel JF. Phenotypic and genomic analysis of mulMple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. Blood. 2016 Apr 14;127(15):1896-906.

Paiva B, Mateos MV, Sanchez-Abarca LI, Puig N, Vidriales MB, López-Corral L, Corchete LA, Hernandez MT, Bargay J, de Arriba F, de la Rubia J, Teruel AI, Giraldo P, Rosiñol L, Prosper F, Oriol A, Hernández J, Esteves G, Lahuerta JJ, Bladé J, Perez-Simon JA, San Miguel JF. Immune status of high-risk smoldering multiple myeloma paMents and its therapeuMc modulation under LenDex: a longitudinal analysis. Blood. 2016 Mar 3;127(9):1151-62.

Vagace JM, Cardesa R, Corbacho A, Vázquez T, de la Maya MD, Gonzalez FA, Nieto JB, UrruMa E, Gómez MJ, Pascual T, Aguinaco MR, Gervasini G. EMopathological mechanisms and clinical characterisMcs of hyperhemolysis syndrome in Spanish paMents with thalassemia. Ann Hematol. 2016 Sep;95(9):1419-27.

Santos N, Rodríguez-Romanos R, Nieto JB, Buño I, Vallejo C, Jiménez-Velasco A, Brunet S, Buces E, López-Jiménez J, González M, Ferrá C, Sampol A, de la Cámara R, Martínez C, Gallardo D. UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-idenMcal sibling donor stem cell transplantaMon. Bone Marrow Transplant. 2016 Jan;51(1):79-82.

Ribera JM, García O, Oriol A, Gil C, Montesinos P, Bernal T, González-Campos J, Lavilla E, Ribera J, Brunet S, Martínez MP, Tormo M, Genescà E, Barba P, Sarrà J, Monteserín MC, Soria B, Colorado M, Cladera A, García-Guiñón A, Calbacho M, Serrano A, Ornn X, Pedreño M, Amigo ML, Escoda L, Feliu E. Feasibility and results of subtype-oriented protocols in older adults and fit elderly paMents with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016 Feb;41:12-20.

Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G. Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia. Eur J Haematol. 2016 Jul;97(1):33-8.

Martínez C, Díaz-López A, Rodriguez-Calvillo M, García-Sanz R, Terol MJ, Pérez-Ceballos E, Jiménez MJ, Cantalapiedra A, Domingo-Domenech E, Rodriguez MJ, Sampol A, Espeso M, López FJ, Briones J, García JF, Sureda A. Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for paMents with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. Br J Haematol. 2016 Sep;174(6): 859-67.

GuMérrez-Cívicos R, Hurtado AM, Torres-Moreno D, Sanchez-Blanco JJ, Español I, Consuegra-Sánchez L, Perez-Ceballos E, GuMérrez-Meca MD, Jerez A, Conesa-Zamora P. A polymorphism in FASL is associated with rituximab response in follicular lymphoma patients. Am J Hematol. 2016 Jun;91(6):E305-7.

Marnn-Marnn L, Almeida J, Pomares H, González-Barca E, Bravo P, Giménez T, Heras C, Queizán JA, Pérez-Ceballos E, Martínez V, Alonso N, Calvo C, Álvarez R, Caballero MD, Orfao A. BlasMc plasmacytoid dendriMc cell neoplasm frequently shows occult central nervous system involvement at diagnosis and benefits from intrathecal therapy. Oncotarget. 2016 Mar 1;7(9):10174-81.

Peñalver FJ, Delgado J, Loscertales J, Sastre JL, Peña A, Olave MT, Osorio S, de la Fuente A, Salar A, Grande C, Pérez Ceballos E, Debén G, Echeveste A, Casado F, de la Rubia J, Lahuerta JJ, Mateos MV. Recommendations on the clinical use of bendamustine in lymphoproliferaMve syndromes and multiple myeloma. Eur J Haematol. 2016 May; 96(5):532-40.

Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa LErythroleukemia shares biological features and outcome with myelodysplasMc syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Mod Pathol. 2016 Dec;29(12): 1541-1551.

Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Díez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes. J Clin Oncol. 2016 Sep 20;34(27):3284-92.

Flores MA, Fortea P, Trinidad EM, García D, Soler G, Ortuño FJ, Zapata AG, Alonso- Colmenar LM. EphrinA4 plays a critical role in α4 and αL mediated survival of human CLL cells during extravasaMon. Oncotarget. 2016 Jul 26;7(30):48481-48500.

Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, Samah A, Griesshammer M, Kerguelen A, Andreasson B, Burgaleta C, Schwarz J, García-GuMérrez V, Ayala R, Barba P, Gómez-Casares MT, Paoli C, Drexler B, Zweegman S, McMullin MF, Samuelsson J, Harrison C, Cervantes F, Vannucchi AM, Besses C. AnMplatelet therapy versus observaMon in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016 Aug;101(8):926-31

Alvarez-Larrán A, Kerguelen A, Hernández-Boluda JC, Pérez-Encinas M, Ferrer-Marín F, Bárez A, Martínez-López J, Cuevas B, Mata MI, García-Gutiérrez V, Aragües P, Montesdeoca S, Burgaleta C, Caballero G, Hernández-Rivas JA, Durán MA, Gómez- Casares MT, Besses C. Frequency and prognosMc value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. Br J Haematol. 2016 Mar; 172(5):786-93.

Gómez M, Guillem V, Pereira A, Ferrer-Marín F, Álvarez-Larrán A, Kerguelen A, Estrada N, Martínez-López J, Angona A, Amat P, Navarro B, Besses C, Hernández-Boluda JC. Risk factors for non-melanoma skin cancer in paMents with essenMal thrombocythemia and polycythemia vera. Eur J Haematol. 2016 Mar;96(3):285-90

Hernández-Boluda JC, Martínez-Trillos A, García-Gutiérrez V, Ferrer-Marín F, Xicoy B, Alvarez-Larrán A, Kerguelen A, Barba P, Gómez M, Herrera JC, Correa JG, Cervantes F. Long-term results of prednisone treatment for the anemia of myelofibrosis. Leuk Lymphoma. 2016;57(1):120-4

Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult paMents with acute lymphoblasMc leukemia treated with riskadapted protocols. Leuk Lymphoma. 2017 Jan;58(1):145-152.

Macauda A, Calvey D, Maccari G, Hemminki K, FörsM A, Goldschmidt H, Weinhold N, Houlston R, Andersen V, Vogel U, Buda G, Varkonyi J, Sureda A, Martínez Lopez J, Watek M, Butrym A, Sarasquete ME, Dudziński M, Jurczyszyn A, Druzd-Sitek A, Kruszewski M, Subocz E, Petrini M, Iskierka-Jażdżewska E, Raźny M, Szombath G, Marques H, Zawirska D, Chraniuk D, Halka J, Hove Jacobsen SE, Mazur G, García Sanz R, Dumontet C, Moreno V, Stępień A, Beider K, Pelosini M, Manuel Reis R, Krawczyk-Kulis M, Rymko M, Avet- Loiseau H, Lesueur F, Grząśko N, Ostrovsky O, Jamroziak K, Vangsted AJ, Jerez A, Tomczak W, Zaucha JM, Kadar K, Sainz J, Nagler A, Landi S, Gemignani F, Canzian F. IdentificaMon of miRSNPs associated with the risk of multiple myeloma. Int J Cancer. 2017 Feb 1;140(3):526-534.

Torregrosa JM, Ferrer-Marín F, Lozano ML, Moreno MJ, Martínez C, Anton AI,Rivera J, Vicente V. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutaMon. Br J Haematol. 2016 Mar;172(5):813-5. Muñoz-Ballester J, Chen-Liang TH, Hurtado AM, Heras I, de Arriba F,García-Malo MD, Iniesta P, Lozano ML, Nieto JB, Ortuño FJ, Osma Mdel M, Padilla J, Teruel-Montoya R, Vicente V, Castilla-Llorente C, Jerez A. Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of STAT3 mutations. Br J Haematol. 2016 Mar;172(6):937-46.

Cervantes F, Correa JG, Pérez I, García-GuMérrez V, Redondo S, Colomer D, Jiménez- Velasco A, Steegmann JL, Sánchez-Guijo F, Ferrer-Marín F, Pereira A, Osorio S . Imatinib dose reducMon in paMents with chronic myeloid leukemia in sustained deep molecular response. Ann Hematol. 2016 Oct 8.

González-Gascón Y Marín I, Martín AÁ, Hernández-Sanchez M, Robledo C, Hermosín ML, de Las Heras N, Lacalle L, Galende J, de Arriba F, Rodríguez-Vicente AE, Hernández JÁ, Hernández-Rivas JM. Hyperdiploidy as a rare event that accompanies poor prognosis markers in CLL. Eur J Haematol. 2016 Sep 26. doi: 10.1111/ejh.12812.

Martínez C, Jorge AS, Pereira A, Moreno M, Núñez J, Gayoso J, Gonzalez-Medina J, Revilla N, Sampol A, Domingo-Domenech E, de la Cruz F, Morales A, Rodriguez-Salazar MJ, Valiente S, Pérez-Ceballos E, de Oteyza JP, García-Sanz R. Comorbidities, not age, are predicMve of survival a}er autologous hematopoietic cell transplantation for relapsed/refractory Hodgkin's lymphoma in patients older than 50 years. Ann Hematol. 2016 Oct 18.

Ríos-Tamayo R, Lupiañez CB, Campa D, Hielscher T, Weinhold N, Martínez-López J, Jerez A, Landi S, Jamroziak K, Dumontet C, Wątek M, Lesueur F, Reis RM, Marques H, Jurczyszyn A, Vogel U, Buda G, García-Sanz R, Orciuolo E, Petrini M, Vangsted AJ, Gemignani F, Försti A, Goldschmidt H, Hemminki K, Canzian F, Jurado M, Sainz J. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis. Oncotarget. 2016 Jul 18. doi: 10.18632/oncotarget.10665.

Blanco G, Puiggros A, Baliakas P, Athanasiadou A, García-Malo M, Collado R, Xochelli A, Rodríguez-Rivera M, Ortega M, Calasanz MJ, Luño E, Vargas M, Grau J, Martínez- Laperche C, Valiente A, Cervera J, Anagnostopoulos A, Gimeno E, Abella E, Stalika E, Hernández-Rivas JM, Ortuño FJ, Robles D, Ferrer A, Ivars D, González M, Bosch F, Abrisqueta P, Stamatopoulos K, Espinet B. Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberraMons. Oncotarget. 2016 Nov 4doi:10.18632/oncotarget. 13106.

Alvarez-Larrán A, Pérez-Encinas M, Ferrer-Marin F, Hernández-Boluda JC, Ramírez MJ, Martínez-López J, Magro E, Cruz Y, Mata MI, Aragües P, Fox ML, Cuevas B, Montesdeoca S, Hernández-Rivas JA, García-GuMérrez V, Gómez-Casares MT, Steegmann JL, Durán MA, Gómez M, Kerguelen A, Bárez A, García MC, Boqué C, Raya JM, Martínez C, Albors M, Garcia F, Burgaleta C, Besses CRisk of thrombosis according to need of phlebotomies in paMents with polycythemia vera treated with hydroxyurea. Haematologica. 2016 Sep 29. pii: haematol.2016.152769.

Publicaciones en 2015

Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol. 2015; 94 (6): 911-8. Torregrosa JM, Soler G, Cancio S, Ferrer-Marin F. Concurrent lymphoid and Philadelphia chromosome-negative myeloproliferative neoplasms. Med Clin (Barc). 2015; 145 (7): 318-9.

Noriega V, Martínez-Laperche C, Buces E, Pion M, Sánchez-Hernández N, Martín- Antonio B, Guillem V, Bosch-Vizcaya A, Bento L, González-Rivera M, Balsalobre P, Kwon M, Serrano D, Gayoso J, de la Cámara R, Brunet S, Rojas-Contreras R, Nieto JB, Martínez C, Gónzalez M, Espigado I, Vallejo JC, Sampol A, Jiménez-Velasco A, Urbano-Ispizua A, Solano C, Gallardo D, Díez-Martín JL, Buño I; Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH).The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect after Myeloablative HLA-Identical Allogeneic Stem Cell Transplantation.PLoS One. 2015; 10 (10): e0140454.

Lopez A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, Perez M, Martínez R, de Paz R, Granell M, De Arriba F, Blanchard MJ, Peñalver FJ, Bello JL, Martín ML, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, de la Rubia J. Pajerns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinaMons. Leuk Res Rep. 2015 Sep 24;4(2):64-9.

Hurtado AM, Chen-Liang TH, Przychodzen B, Hamedi C, Muñoz-Ballester J, Dienes B, García-Malo MD, Antón AI, de Arriba F, Teruel-Montoya R, Ortuño FJ, Vicente V, Maciejewski JP, Jerez A.Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. Blood Cancer J. 2015;5:e342.

Noriega V, Martínez-Laperche C, Buces E, Pion M, Sánchez-Hernández N, Martín- Antonio B, Guillem V, Bosch-Vizcaya A, Bento L, González-Rivera M, Balsalobre P, Kwon M, Serrano D, Gayoso J, de la Cámara R, Brunet S, Rojas-Contreras R, Nieto JB, Martínez C, Gónzalez M, Espigado I, Vallejo JC, Sampol A, Jiménez-Velasco A, Urbano-Ispizua A, Solano C, Gallardo D, Díez-Martín JL, Buño I.The Genotype of the Donor for the (GT)n Polymorphism in the Promoter/Enhancer of FOXP3 Is Associated with the Development of Severe Acute GVHD but Does Not Affect the GVL Effect a}er MyeloablaMve HLAIden Mcal Allogeneic Stem Cell Transplantation. PLoS One. 2015 Oct 16;10(10):e0140454.

Sánchez Guiu IM, Martínez-Martinez I, Martínez C, Navarro-Fernandez J, García- Candel F, Ferrer-Marín F, Vicente V, Watson SP, Andrews RK, Gardiner EE, Lozano ML, Rivera J.An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets.ThrombHaemost. 2015 Aug; 114 (2):313-24.

Soler G, Bernal-Vicente A, Antón AI, Torregrosa JM, Caparrós-Pérez E, Sánchez- Serrano I, Martínez-Pérez A, Sánchez-Vega B, Vicente V, Ferrer-Marin F.The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms. Ann Hematol. 2015; 94 (5):789-94.

Castro-Villegas C, Pérez-Sánchez C, Escudero A, Filipescu I, Verdu M, Ruiz-Limón P, Aguirre MA, Jiménez-Gomez Y, Font P, Rodriguez-Ariza A, Peinado JR, Collantes- Estévez E, González-Conejero R, Martinez C, Barbarroja N, López-Pedrera C.Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFα. Arthritis Res Ther. 2015 Mar 9;17:49.

Ortuño FJ, Sola M.Extreme dyserythropoiesis in the setting of acute erythroid leucemia. Blood. 2015 Sep 10;126(11):1391

Chen-Liang TH, Martin-Santos T, Jerez A, Senent L, Orero MT, Remigia MJ, Muiña B, Romera M, Fernandez-Muñoz H, Raya JM, Fernandez-Gonzalez M, Lancharro A, Villegas C, Carlos Herrera J, Frutos L, Luis Navarro J, Uña J, Igua C, Sanchez-Vaño R, CozarMdel P, Contreras J, Sanchez-Blanco JJ, Perez-Ceballos E, Ortuño FJ.The role of bone marrow biopsy and FDG-PET/CT in identifying bone marrow infiltration in the initial diagnosis of high grade non-Hodgkin B-cell lymphoma and Hodgkin lymphoma.Accuracy in a multicenter series of 372 patients. Am J Hematol. 2015;90 (8): 686-90.

Varney ME, Niederkorn M, Konno H, Matsumura T, Gohda J, Yoshida N, Akiyama T, Christie S, Fang J, Miller D, Jerez A, Karsan A, Maciejewski JP, Meetei RA, Inoue J, Starczynowski DT. Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling. J Exp Med. 2015; 212 (11): 1967-85.

Bilori B, Thota S, Clemente MJ, Patel B, Jerez A, Afable Ii M, Maciejewski JP.Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Leukemia. 2015; 29 (12):2427-9.

Saumell S, Solé F, Arenillas L, Montoro J, Valcárcel D, Pedro C, Sanzo C, Luño E, Giménez T, Arnan M, Pomares H, De Paz R, Arrizabalaga B, Jerez A, Martínez AB, Sánchez-Castro J, Rodríguez-Gambarte JD, Raya JM, Ríos E, Rodríguez-Rivera M, Espinet B, Florensa L.Trisomy 8, a Cytogenetic Abnormality in Myelodysplastic Syndromes, Is Constitutional or Not?. PLoSOne. 2015; 10 (6):e0129375.

Ríos R, Lupiañez CB, Campa D, Martino A, Martínez-López J, Martínez-Bueno M, Varkonyi J, García-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wętek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczyszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. Endocr Relat Cancer. 2015; 22 (4):545-59.

Chen-Liang TH, Jerez A, Florensa L, Ortuño FJ.Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia.Med Clin (Barc). 2015; 144 (12):571-2.

McGraw KL, Zhang LM, Rollison DE, Basiorka AA, Fulp W, Rawal B, Jerez A, Billingsley DL, Lin HY, Kurtin SE, Yoder S, Zhang Y, Guinta K, Mallo M, Solé F, Calasanz MJ, Cervera J, Such E, González T, Nevill TJ, Haferlach T, Smith AE, Kulasekararaj A, Mufti G, Karsan A, Maciejewski JP, Sokol L, Epling-Burnette PK, Wei S. List AF The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes. Blood Cancer J. 2015; 5:e291.

Rajala HL, Olson T, Clemente MJ, Lagström S, Ellonen P, Lundan T, Hamm DE, Zaman SA, Lopez Marti JM, Andersson EI, Jerez A, Porkka K, Maciejewski JP, Loughran TP, Mustjoki S. The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia.Haematologica. 2015; 100 (1):91-9.

Lopez A, Mateos MV, Oriol A, Valero M, Martínez J, Lorenzo JI, Perez M, Martinez R, de Paz R, Granell M, De Arriba F, Blanchard MJ, Peñalver FJ, Bello JL, Martin ML, Bargay J, Blade J, Lahuerta JJ, San Miguel JF, de la Rubia J. Patterns of relapse and outcome of elderly multiple myeloma patients treated as front-line therapy with novel agents combinations.Leuk Res. 2015; 4 (2):64-9.

Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group. Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality. Blood. 2015; 126 (7):858-62.

Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste MA, Sarrá J, Ocio E, Ramírez G, Martínez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea AI, Bladé J, Lahuerta JJ, San Miguel JF. Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.Haematologica. 2015; 100 (8):1096-102.

Bernal T, Martínez-Camblor P, Sánchez-García J, de Paz R, Luño ENomdedeu B, Ardanaz MT, Pedro C, Amigo ML, Xicoy B, del Cañizo C, Tormo M, Bargay J, Valcárcel D, Brunet S, Benlloch L, Sanz G; Spanish Group on Myelodysplastic Syndromes; PETHEMA Foundation; Spanish Society of Hematology. Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia. 2015; 29 (9):1875-81.

Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J; Cooperative AML group CETLAM. The lincregion, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. RNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.Oncotarget. 2015; 6 (31):31613-27.

Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J. The expression level of BAALCassociated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.Blood Cancer J. 2015; 5:e352.

García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, Martí-Tutusaus JM, Heras I, Garcia A, Salamero O, Aventin A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF.Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML.Am J Clin Pathol. 2015; 144 (3):484-92.

Martino R, Bautista G, Parody R, García I, Esquirol A, Rovira M, Cabrera JR, Regidor C, Fores R, García-Marco JA, Serrano D, Barba P, Heras I, Marquez-Malaver FJ, Sánchez-Ortega I, Duarte R, Saavedra S, Sierra J, Vazquez L; Infectious/Non-infectious Complications Subcommittee of the Grupo Español de Trasplante Hematopoyético. Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the GrupoEspañol de TrasplanteHematopoyético (GETH). Transpl Infect Dis. 2015; 17 (2):221-33.

Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J; Cooperative AML group CETLAM. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediaterisk cytogenetic category, and is associated with a distinctive microRNA signature.Oncotarget. 2015; 6 (31):31613-27.

Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J. The expression level of BAALCassociated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.Blood Cancer J. 2015; 5:e352.

García-Dabrio MC, Hoyos M, Brunet S, Tormo M, Ribera JM, Esteve J, Gallardo D, Duarte RF, de Llano MP, Bargay J, Martí-Tutusaus JM, Heras I, Garcia A, Salamero O, Aventin A, Lecrevisse Q, Orfao A, Sierra J, Nomdedéu JF.Complex measurements may be required to establish the prognostic impact of immunophenotypic markers in AML.Am J Clin Pathol. 2015; 144 (3):484-92.

Fox ML, Barba P, Heras I, López-Parra M, González-Vicent M, de la Cámara R, Batlle M, Parody R, Vallejo C, Ruiz-Camps I, Vázquez L; Infectious and Non-Infectious Complicatio ns Subcommittee of the Spanish Haematopoietic Transplant Group (GrupoEspañol de TrasplanteHematopoyético; GETH). A registry-based study of non- Aspergillus mould infections in recipients of allogeneic haematopoietic cell transplantation.Clin Microbiol Infect. 2015; 21(1):e1-3.

Parody R, Martino R, de la Cámara R, García-Noblejas A, Esquirol A, Garcia-Cadenas I, Villaescusa T, Caballero D, Rovira M, Fernandez-Avilés F, Marquez-Malaver FJ, Espigado I, Castilla-Llorente C, Heras I, Cabero MA, Cabrera JR, Barba P, Valcarcel D, Sánchez-Ortega I, Duarte RF, Serrano D, Carretero F, Vazquez L.Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: improving outcomes over time.Bone Marrow Transplant. 2015; 50 (2):274-81.

Aguado JM, Vázquez L, Fernández-Ruiz M, Villaescusa T, Ruiz-Camps I, Barba P, Silva JT, Batlle M, Solano C, Gallardo D, Heras I, Polo M, Varela R, Vallejo C, Olave T, López-Jiménez J, Rovira M, Parody R, Cuenca-Estrella M; PCRAGA Study Group; Spanish Stem Cell Transplantation Group; Study Group of Medical Mycology of the Spanish Society of Clinical Microbiology and Infectious Diseases; Spanish Network for Research in Infectious Diseases. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis. 2015; 60 (3):405-14

Ferrà C, Sanz J, Díaz-Pérez MA, Morgades M, Gayoso J, Cabrera JR, Villaescusa T, Sampol MA, Fernández-Avilés F, Solano C, Ortín M, Duarte R, Cuesta M, Heras I, de la Serna J, Moraleda JM, Barrenetxea C, González-Vicent M, Sanz G, Ribera JM; Grupo Español de Trasplante Hematopoyético (Geth) Spanish Society of Hematology.Outcome of graft failure after allogeneic stem cell transplant: study of 89 patients. Leuk Lymphoma. 2015; 56 (3): 656-62.